Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Abstract Background Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and over...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Thanaporn Bussabawalai, Kittiphong Thiboonboon, Yot Teerawattananon
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2019-01-01
Series:Cost Effectiveness and Resource Allocation
Assuntos:
Cost-utility analysis
Adjuvant imatinib
Recurrence
Gastrointestinal stromal tumour
GIST
Acceso en liña:http://link.springer.com/article/10.1186/s12962-018-0169-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares